Merrill keeps Amylin at neutral

Amylin Pharmaceuticals was maintained by Merrill Lynch analyst Tom McGahren at neutral after the company posted a loss of $0.36 per share in the third quarter. Byetta sales of $126 million just beat the analyst's estimate of $125 million, and margins were higher than expected. However, Amylin expenses will rise as the result of marketing Byetta. Merrill raised its 2006 Byetta sales estimate slightly to $451million, from $443 million. Shares of the San Diego-based biopharmaceutical company were down 97 cents, or 2.04%, at $46.48. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.